Tag: nasdaq:mbio

December 9, 2019

Mustang Bio Announces Additional Clinical Data on MB-107

The company announced that updated Phase 1/2 clinical data for MB-107 was presented at the 61st American Society of Hematology...
August 27, 2019

Mustang Bio Announces License Agreement with CSL Behring

Mustang Bio (NASDAQ:MBIO) has announced it has entered into a license agreement with CSL Behring for the Cytegrity stable producer...
August 22, 2019

Mustang Bio and St. Jude Children’s Research Hospital Receives RMAT Designation from FDA

Mustang Bio (NASDAQ:MBIO) and St. Jude Children’s Research hospital have announced that MB-107, a gene therapy to treat X-linked severe...
August 18, 2019

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Novavax Up 82 Percent

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
August 13, 2019

Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103

Mustang Bio (NASDAQ:MBIO) has announced a US$9.28 million grant from the California Institute for Regenerative Medicine (CIRM) to fund an...
July 24, 2019

Mustang Bio Receives Orphan Drug Designation for MB-102

Mustang Bio (NASDAQ:MBIO) announced it has received orphan drug designation from the US Food and Drug Administration (FDA) For its...
May 8, 2019

Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein

Mustang Bio (NASDAQ:MBIO) has announced that City of Hope, a cancer research and treatment center, has started enrolling patients with...